CA Patent

CA2769525A1 — Therapeutic agents for reducing parathyroid hormone levels

Assigned to Kai Pharmaceuticals Inc · Expires 2011-02-03 · 15y expired

What this patent protects

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1 - X2 - X3 - X4 - X5 - X6 - X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution …

USPTO Abstract

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1 - X2 - X3 - X4 - X5 - X6 - X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Drugs covered by this patent

Patent Metadata

Patent number
CA2769525A1
Jurisdiction
CA
Classification
—
Expires
2011-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Kai Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.